Best Life Sciences Companies in Suzhou, China
The 97 best Life Sciences companies in Suzhou, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abogen Biosciences.
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Suzhou
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Abogen Biosciences 🦄 Developer of mRNA-based therapeutics for cancer and infectious diseases 55Moat top 14%Patents top 17%Innovation top 22%Funding top 27% All 8 signals ▾Moattop 14% Patentstop 17% Innovationtop 22% Fundingtop 27% Talenttop 38% Marketbottom 44% Globalbottom 43% Techbottom 24% Moat: Editorial + unicorn rating 9/10 · IP moat: 157 patents Patents: 157 patents matched (strict assignee match) · 154 filings since 2022 vs 3 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $1.1B | 49 mo ago | Series C | — | 2019 | Dr InBev Co-Founder & Co-CEO | 157 patents mRNA and circular RNA therapeutics with lipid nanoparticle delivery systems | — |
| 2 | Innovent Bio Developer of antibody therapeutics for multiple diseases | $535M | 46 mo ago | Public | 5,144 | 2011 | Michael Yu Founder & CEO | — | 1 partnership |
| 3 | Transcenta Developer of antibody-based therapeutics | $205M | 66 mo ago | Public | 318 | 2019 | Xueming Qian Co-Founder & CEO | — | — |
| 4 | Souzhou Ribo Life Science Developer of nucleic acid drugs based on RNA interference (RNAi) technology | $201M | 46 mo ago | Public | 228 | 2007 | Zicai Liang Founder | — | — |
| 5 | Frontera Therapeutics Developer of AAV-based gene therapies for the treatment of rare and chronic diseases | $195M | 47 mo ago | Series B | 41 | 2019 | — | — | — |
| 6 | Suzhou Connect Biopharmaceuticals Discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation | $195M | 69 mo ago | Public | 100 | 2012 | Zheng Wei Co-Founder & CEO | 87 patents Therapeutic antibodies targeting IL‑4Rα and novel S1P1 receptor agonist salts | — |
| 7 | Alphamab Oncology 🦄 Developer of antibodies for the treatment of cancer diseases | $160M | 84 mo ago | Public | 31 | 2009 | — | — | — |
| 8 | Adagene Developer of immunotherapy for the treatment of cancer 37Funding top 18%Product top 24%Moat top 38%Tech top 42% All 12 signals ▾Fundingtop 18% Producttop 24% Moattop 38% Techtop 42% Globaltop 43% Partnerstop 45% Patentstop 46% Talentbottom 49% Growthbottom 42% Innovationbottom 38% Marketbottom 36% Newsbottom 23% Funding: Raised $157M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) Product: 2 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 37/100 | $157M | 11 mo ago | Public | 15 | 2012 | Peter Luo Founder & CEO | 26 patents Antibody library engineering and heterodimeric Fc protein therapeutics for cancer treatment | — |
| 9 | Sinovent Developer of small molecule drugs for the treatment of tumour, CNS, autoimmunity, and infectious disease | $145M | 65 mo ago | Deadpooled | 50 | 2017 | Jing Qiang Founder | — | — |
| 10 | Doma Pharmaceutical Technology Developer of drugs for the treatment of cancer | $142M | 48 mo ago | Series A | — | 2021 | Shen Yuelei Chairman | — | — |
| 11 | Virtue Diagnostics Provider of an in vitro assay platform for diagnostic solutions | $130M | 53 mo ago | Series B | 500 | 2019 | Johnson Zhang CEO | — | 1 job opening |
| 12 | MediLink Developer of antibody-drug conjugates for cancer treatment | $120M | 51 mo ago | Series B | 49 49 → 60 (+22%) | 2020 | Jiaqiang Cai Co-Founder & CSO | — | — |
| 13 | Peijia Medical Technologies Developer of medical devices for the treatment of cardiac and cerebrovascular diseases | $110M | 79 mo ago | Public | 1,006 | 2012 | — | — | — |
| 14 | Tot Biopharm Chinese oncology drug development and manufacturing company | $108M | 94 mo ago | Series B | — | 2010 | — | — | — |
| 15 | Evopoint Developer of therapeutics for multiple diseases | $97M | 28 mo ago | Series E | — | 2017 | Nianfeng Ju Co-Founder | — | — |
| 16 | Eluminex Biosciences Developer of therapeutics for ocular disorders | $90M | 39 mo ago | Series B | 65 | 2019 | JZ Zhang Founder & CEO | 27 patents Multispecific antibody‑fusion biologics targeting IL‑6/angiogenesis and ocular retinoid therapies | — |
| 17 | CureGenetics Provider of CRISPR-Cas9 based gene-editing technology for therapy and diagnosis | $79M | 53 mo ago | Series B | 17 | 2016 | Yanni Lin Co-founder and Chief Scientist | — | — |
| 18 | CMAB Biopharma Developer and manufacturer of biologic products | $72M | 98 mo ago | Acqui-Hired | 250 | 2017 | — | — | — |
| 19 | SceneRay Developer of a portfolio of Neuromodulation devices | $63M | 52 mo ago | Series D | 29 | 2011 | — | 158 patents Neuromodulation devices and surgical planning systems for targeted nerve stimulation | 1 partnership |
| 20 | Accropeutics Developer of drugs for inflammation, autoimmune diseases, and cancer 57Funding top 20%Talent top 38%Market bottom 49%Global bottom 48% All 4 signals ▾Fundingtop 20% Talenttop 38% Marketbottom 49% Globalbottom 48% Funding: Raised $62.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 57/100 | $62M | 1 mo ago | Series C | — | 2017 | Xiaohu Zhang Co-Founder & CEO | — | — |
| 21 | Beikang Medical Developer of NGS-based diagnostic solutions for neonatal | $37M | 73 mo ago | Public | 488 | 2010 | — | — | — |
| 22 | Qinhao Pharmaceutical Developer of small-molecule therapeutics for tumor and fibrosis | $31M | 52 mo ago | Series B | 14 | 2014 | Kuifeng Wang Founder & CEO | — | — |
| 23 | Sniper Developer of droplet digital PCR | $31M | 56 mo ago | Series B | — | 2018 | Sheng Guangji Founder | — | — |
| 24 | CGene Tech Developer of drug discovery platform | $30M | 82 mo ago | Series A | — | 2010 | John Yu CEO | — | — |
| 25 | 4B Technologies Developer of drugs for neurological disorders | $25M | 42 mo ago | Series A | 9 | 2018 | Liu Jie Co-Founder | — | — |
| 26 | Starna Therapeutics Developer of RNA-based drugs for multiple diseases 29Funding top 34%Moat top 38%Talent bottom 49%Market bottom 37% All 5 signals ▾Fundingtop 34% Moattop 38% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $22.1M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $22M | 8 mo ago | Series B | — | 2021 | Rongkuan Hu Founder | — | — |
| 27 | PegBio Developer of therapeutic solutions for treating type II diabetes and rheumatoid arthritis | $22M | 66 mo ago | Public | 53 | 2007 | — | 36 patents Pegylated exenatide peptide therapeutics for glucose metabolism disorders | — |
| 28 | Kossel Medtech Developer of cardiovascular medical devices | $16M | 29 mo ago | Series B | — | 2013 | Navis Feng Co-Founder | 6 patents Patents concentrated in health & consumer products | — |
| 29 | magAssist Developer of extracorporeal circulation assisting device | $15M | 56 mo ago | Series C | — | 2017 | Polin Hsu Founder | 100 patents Design and integration of catheter pump systems for ventricular assist and fluid management | 1 award |
| 30 | Innovel Intelligent Technology Provider of bioreactors for cell culture | $15M | 62 mo ago | Series A | — | 2018 | Hao Chen Founder & CEO | 23 patents Automated oscillating culture vessels and integrated macromolecule extraction/purification systems | — |
| 31 | Healrna Developer of nucleic acid drugs to treat various diseases | $15M | 39 mo ago | Seed | — | 2021 | Zhong Tianyi Co-Founder & CEO | — | — |
| 32 | Suzhou Nanomicro Technology Nano and micro particles manufacturer | $14M | 91 mo ago | Series A | 820 | 2007 | — | — | — |
| 33 | Convergen Pharmaceuticals Provider of a platform utilizing Generative AI to accelerate drug discovery and development for the biotech… 48Funding top 41%AI top 45%Talent bottom 45%Global bottom 33% All 4 signals ▾Fundingtop 41% AItop 45% Talentbottom 45% Globalbottom 33% Funding: Raised $10.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: generative ai rank vs industry peers · Fliar Intelligence Index 48/100 | $10M | 6 mo ago | Seed | — | 2020 | Jinquan Sun Co-Founder & CEO | — | — |
| 34 | Big Vision Provider of ophthalmology diagnosis and analysis systems | $9M | 25 mo ago | Series A | — | 2015 | Chen Xinjian Founder | — | — |
| 35 | InnoBM Developer of immunotherapeutics for cancer treatment | $7M | 45 mo ago | Series A | — | 2019 | Zhuang Liu Founder | — | — |
| 36 | Suzhou Junhui Biotechnology Specializes in the development of single-cell assays for clinical applications | $2M | 103 mo ago | Seed | — | 2015 | Yan Zhuo Hui Founder | — | — |
Top 12 Life Sciences companies in Suzhou
#1
Series C · Suzhou, Jiangsu · founded 2017$62Mraised▾
Developer of drugs for inflammation, autoimmune diseases, and cancer. The pipeline includes AC-003 Receptor -interacting protein kinase1 for Idiopathic pulmonary fibrosis, Graft versus Host Disease, AC-101 for inflammatory bowel disease, AC-201, an allosteric TYK2/JAK1 inhibitor for psoriasis, and others.
- May 2026Series C$50M
- Mar 2025Series B$12M
#2
Public · Suzhou, Jiangsu · founded 2012 · 15 employees$157.4Mraised▾
Developer of immunotherapy for the treatment of cancer. It is developing antibodies which include ADG106 which is an agonist for CD137 in metastatic solid tumors, ADG126 targets CTLA4 for cancer therapy, and aADG116 targets epitope of CTLA4 in metastatic solid tumors and relapsed/refractory non-Hodgkin’s lymphoma.
- Jul 2025Post IPO$25M
- Jan 2020Series D$69M
- Mar 2018Series C$50M
- Jan 2016Series B$28M
#3
Series B · Suzhou, Jiangsu · founded 2021$22.1Mraised▾
Developer of RNA-based drugs for multiple diseases. The company focuses on the development of innovative drugs and vaccines with RNA as the core for infectious diseases, tumor immunology, and metabolic diseases.
- Oct 2025Series B$44M
- May 2022Series A$22.1M
- Dec 2021Angel—
#4
Seed · Suzhou, Jiangsu · founded 2020$10Mraised▾
Provider of a platform utilizing Generative AI to accelerate drug discovery and development for the biotech and pharmaceutical industries. It utilises the power of Large Language Models specifically trained on biological languages to discover and develop effective drugs.
- Dec 2025Seed$10M
#5
Series C · Suzhou, Jiangsu · founded 2019$1.1Braised▾
Developer of mRNA-based therapeutics for cancer and infectious diseases. The company has developed proprietary technology platforms in mRNA design, in vitro synthesis, and LNP-based delivery systems to develop targeted therapies for infectious and immuno-oncology indications.
- May 2022Series C—
- Nov 2021Series C$300M
- Aug 2021Series C$720M
- Apr 2021Series B$91.6M
#6
Public · Suzhou, Jiangsu · founded 2011 · 5144 employees$535Mraised▾
Developer of antibody therapeutics for multiple diseases. It offers monoclonal and bispecific antibodies to treat several cancers such as non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, colorectal cancer, and lung cancer. Also, has antibody binding to TNF-α preventing it from activating TNF receptors, and will be used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s disease, and other autoimmune diseases.
- Aug 2022Post IPO$307.9M
- Oct 2019Post IPO$299.8M
- Apr 2018Series E$150M
- Nov 2016Series D$260M
#7
Series E · Suzhou, Jiangsu · founded 2017$97.3Mraised▾
Developer of therapeutics for multiple diseases. It offers a drug pipeline that includes BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and antibody-drug conjugates for the treatment of cancer, infectious disease, and metabolic disease.
- Feb 2024Series E$97.3M
#8
Public · Suzhou, Jiangsu · founded 2007 · 228 employees$200.8Mraised▾
Developer of nucleic acid drugs based on RNA interference (RNAi) technology. The company focuses on RNAi technology, drug discovery, siRNA design and screening, chemical modification, delivery technology, PD/PK study, safety evaluation, clinical trial, and other related aspects. Also, offers siRNA therapeutics against Hepatitis B, breast carcinoma, liver fibrosis, liver carcinoma, HIV, etc.
- Jul 2022Series E$40M
- Apr 2020Series C$66.2M
- Dec 2019Series C$28.8M
- Mar 2017Series B$39.1M
#9
Series B · Suzhou, Jiangsu · founded 2019 · 41 employees$195Mraised▾
Developer of AAV-based gene therapies for the treatment of rare and chronic diseases. The company focuses on developing recombinant AVV products for the treatment of genetic disorders including those of ophthalmology, liver, metabolic, and neuromuscular diseases.
- Jun 2022Series B$160M
#10
Series B · Suzhou, Jiangsu · founded 2019 · 65 employees$90Mraised▾
Developer of therapeutics for ocular disorders. It offers a pipeline of drug candidates EB-101 for wet AMD, EB-102 for diabetic macular edema, EB-105 for retinal vascular diseases, EB-108 for wet AMD, and others.
- Feb 2023Series B$40M
- Nov 2020Series A$50M
#11
Series A · Suzhou, Jiangsu · founded 2021$142.1Mraised▾
Developer of drugs for the treatment of cancer. The company's mission is to focus on technological innovation, continuous new drug production, and safeguarding human health.
- Jun 2022Series A$142.1M
#12
Series B · Suzhou, Jiangsu · founded 2020 · 49 employees$120Mraised▾
Developer of antibody-drug conjugates for cancer treatment. It offers pipeline drug candidates that bind to tumor-specific targets and delivers toxins into cells through endocytosis. It is used to treat small cell lung cancer, prostate cancer, and esophageal squamous cell carcinoma.
- Mar 2022Series B$70M
- Mar 2021Series A$50M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Suzhou researches in biotechnology
Suzhou University of Science and Technology and allied institutions lead optimistic research (mean stance 0.54) on cancer nanotheranostics and biosensing, with breakthroughs dominating recent output.
- Suzhou Research Institute6
- Suzhou University of Science and Technology6
- Suzhou Municipal Hospital5
- Suzhou Institute of Biomedical Engineering and Technology5
- Suzhou Traditional Chinese Medicine Hospital3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.